NCT02676154View on ClinicalTrials.gov

Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI)

PHASE2CompletedINTERVENTIONAL
Enrollment

15

Participants

Timeline

Start Date

February 25, 2016

Primary Completion Date

January 31, 2019

Study Completion Date

January 31, 2019

Conditions
Autonomic Dysreflexia
Interventions
DRUG

Fesoterodine

4mg, oral, once daily for 12 weeks; dose adjustments may be permitted.

Trial Locations (1)

V5Z 1M9

University of British Columbia, Vancouver

Sponsors

Collaborators (1)

Pfizer
All Listed Sponsors
collaborator

Pfizer

INDUSTRY

collaborator

International Collaboration on Repair Discoveries

OTHER

collaborator

Vancouver Coastal Health

OTHER_GOV

lead

University of British Columbia

OTHER

NCT02676154 - Fesoterodine for Amelioration of Autonomic Dysreflexia (AD) Following Spinal Cord Injury (SCI) | Biotech Hunter | Biotech Hunter